Lei Fan1, Danxia Yu1, Xiangzhu Zhu1, Xiang Huang1, Harvey J Murff2, M Andrea Azcarate-Peril3, Martha J Shrubsole1, Qi Dai4. 1. Department of Medicine, Division of Epidemiology, Vanderbilt Epidemiology Center, Vanderbilt University Medical Center, Nashville, TN, USA. 2. Veterans Health Administration-Tennessee Valley Healthcare System Geriatric Research Education Clinical Center (GRECC), HSR&D Center, Vanderbilt University Medical Center, Nashville, TN, USA. 3. Department of Medicine, Division of Gastroenterology and Hepatology, and UNC Microbiome Core, Center for Gastrointestinal Biology and Disease, School of Medicine, University of North Carolina, Chapel Hill, NC, USA. 4. Department of Medicine, Division of Epidemiology, Vanderbilt Epidemiology Center, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: qi.dai@vanderbilt.edu.
Abstract
BACKGROUND & AIMS: Circulating levels of imidazole propionate (ImP), a microbial metabolite of histidine, were higher in participants with type 2 diabetes (T2D) compared to those without and also induced insulin resistance. We hypothesize that low intake of magnesium (Mg) and/or low body Mg status in humans may lead to low Mg concentrations in gut microbiota, and, in turn, elevated microbial production of ImP and increased levels of circulating ImP. METHODS: We tested this hypothesis in the Personalized Prevention of Colorectal Cancer Trial (PPCCT) (registered at clinicaltrials.gov as NCT01105169), a double-blind 2 × 2 factorial randomized controlled trial enrolling 240 participants at high risk of Mg deficiency. Among 68 participants (34 each in the treatment and placebo arms), we measured plasma metabolites using the untargeted Metabolon's global Precision Metabolomics™ LC-MS platform. RESULTS: Mg treatment significantly reduced ImP by 39.9% compared to a 6.0% increase in the placebo arm (P = 0.02). We found the correlation coefficients were -0.12 (P = 0.32) and -0.31 (P < 0.01) between the change in ImP and changes in serum Mg and urinary Mg, respectively. In addition, we found Mg treatment increased circulating levels of propionic acid (InP) by 27.5% (P = 0.07) and reduced levels of glutarate by 17.9% (P = 0.04) compared to the placebo arm. CONCLUSIONS: Further studies are needed to replicate these findings and to investigate whether Mg treatment specifically changes the production of ImP by microbiota. Also, future studies are warranted to confirm the effect of Mg treatment on glutarate and InP.
BACKGROUND & AIMS: Circulating levels of imidazole propionate (ImP), a microbial metabolite of histidine, were higher in participants with type 2 diabetes (T2D) compared to those without and also induced insulin resistance. We hypothesize that low intake of magnesium (Mg) and/or low body Mg status in humans may lead to low Mg concentrations in gut microbiota, and, in turn, elevated microbial production of ImP and increased levels of circulating ImP. METHODS: We tested this hypothesis in the Personalized Prevention of Colorectal Cancer Trial (PPCCT) (registered at clinicaltrials.gov as NCT01105169), a double-blind 2 × 2 factorial randomized controlled trial enrolling 240 participants at high risk of Mg deficiency. Among 68 participants (34 each in the treatment and placebo arms), we measured plasma metabolites using the untargeted Metabolon's global Precision Metabolomics™ LC-MS platform. RESULTS: Mg treatment significantly reduced ImP by 39.9% compared to a 6.0% increase in the placebo arm (P = 0.02). We found the correlation coefficients were -0.12 (P = 0.32) and -0.31 (P < 0.01) between the change in ImP and changes in serum Mg and urinary Mg, respectively. In addition, we found Mg treatment increased circulating levels of propionic acid (InP) by 27.5% (P = 0.07) and reduced levels of glutarate by 17.9% (P = 0.04) compared to the placebo arm. CONCLUSIONS: Further studies are needed to replicate these findings and to investigate whether Mg treatment specifically changes the production of ImP by microbiota. Also, future studies are warranted to confirm the effect of Mg treatment on glutarate and InP.
Authors: Ara Koh; Antonio Molinaro; Marcus Ståhlman; Muhammad Tanweer Khan; Caroline Schmidt; Louise Mannerås-Holm; Hao Wu; Alba Carreras; Heeyoon Jeong; Louise E Olofsson; Per-Olof Bergh; Victor Gerdes; Annick Hartstra; Maurits de Brauw; Rosie Perkins; Max Nieuwdorp; Göran Bergström; Fredrik Bäckhed Journal: Cell Date: 2018-10-25 Impact factor: 41.582
Authors: Qi Dai; Xiangzhu Zhu; JoAnn E Manson; Yiqing Song; Xingnan Li; Adrian A Franke; Rebecca B Costello; Andrea Rosanoff; Hui Nian; Lei Fan; Harvey Murff; Reid M Ness; Douglas L Seidner; Chang Yu; Martha J Shrubsole Journal: Am J Clin Nutr Date: 2018-12-01 Impact factor: 7.045
Authors: Cristina Menni; Jialing Zhu; Caroline I Le Roy; Olatz Mompeo; Kristin Young; Casey M Rebholz; Elizabeth Selvin; Kari E North; Robert P Mohney; Jordana T Bell; Eric Boerwinkle; Tim D Spector; Massimo Mangino; Bing Yu; Ana M Valdes Journal: Gut Microbes Date: 2020-06-24
Authors: Ara Koh; Louise Mannerås-Holm; Na-Oh Yunn; Peter M Nilsson; Sung Ho Ryu; Antonio Molinaro; Rosie Perkins; J Gustav Smith; Fredrik Bäckhed Journal: Cell Metab Date: 2020-08-11 Impact factor: 27.287
Authors: Valentina Trapani; Andrea Rosanoff; Shadi Baniasadi; Mario Barbagallo; Sara Castiglioni; Fernando Guerrero-Romero; Stefano Iotti; André Mazur; Oliver Micke; Guitti Pourdowlat; Giuliana Scarpati; Federica I Wolf; Jeanette A Maier Journal: Eur J Nutr Date: 2021-10-23 Impact factor: 5.614